The Indian Patent Office has attempted to bridge the divide between the laws on patents and biological diversity, but instead it created a maze of problems, says Vidisha Garg of Anand and Anand.
There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.
Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.
Variable sequence IP is fertile ground for potential validity challenges based on prior art or lack of enablement, as Ellen Sherin of GQ Life Sciences reports.
The ChinaBio Partnering Forum, which will be held in Suzhou from April 25 to 26, is celebrating its tenth anniversary and is expected to attract pharma and biotech companies from around the world.
There is a complex relationship between the advancing global bioeconomy and the regulatory frameworks covering access to genetic resources, says Diana Jungmann of Di Blasi Parente & Associados.
The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.
The 12th annual BIO-Europe Spring conference, to be held in Amsterdam, the Netherlands on March 12 to 14, 2018, will allow key players in the biotech industry to come together, as Catherine Moreno Finan reports.
Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.